2025 Q4 -tulosraportti
Vain PDF
80 päivää sitten
Tarjoustasot
Euronext Growth Oslo
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 13.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 13.11.2025 | ||
2025 Q2 -tulosraportti 14.8.2025 | ||
2025 Q1 -tulosraportti 10.4.2025 | ||
2024 Q4 -tulosraportti 13.2.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·29.4.Perhaps this could be significant for Induct in the long term: AstraZeneca has received significant US regulatory approvals for two of its key medicines: Breztri for asthma treatment and Saphnelo for self-administration in systemic lupus erythematosus (SLE). These approvals expand treatment options and convenience for patients. The company is also preparing to publish its first-quarter report, while analysts maintain a positive view on the stock. AstraZeneca's Breztri Aerosphere received US FDA approval for maintenance treatment of asthma in adult and pediatric patients aged 12 years and older, marking its second indication after COPD. The US FDA approved Saphnelo (anifrolumab) for self-administration via a once-weekly autoinjector (Saphnelo Pen) for adult patients with systemic lupus erythematosus (SLE), improving patient convenience and accessibility.
·3 päivää sitten@Kontormannen can you just stop writing. You show that you have zero insight into the case and every word you come up with is just garbage that provides negative value for a potentially constructive conversation.. It's healthy to bring up potential negative aspects of a company, but garbage belongs in the trash can..
·28.4.Slides from the presentation: https://www.healthinnovationoxford.org/wp-content/uploads/2026/04/RTP-Launch-Webinar-23-April-slides-1.pdf recording: https://youtu.be/ZwawwQR0c1c
·28.4.Who is constantly selling? Is there anyone with an endless number of shares? Is anyone benefiting from selling cheap? Anyone following the largest positions and can say something? This is the least shareholder-friendly company I have owned, considering the lack of info and marketing. It's going incredibly slow from the company's side, which still has yet to deliver on expectations…
·29.4.As several have mentioned previously, it is likely Kimpot AS and NPP Capital who have sold off large stakes. Whether this is the case now is not known, as I don't have the latest figures.
2 päivää sitten2 päivää sittenTämä julkaisu on poistettu.·27.4. · Muokattu@Eivloek I find no connection between OPTIMISE and Induct's module in Portsmouth. OPTIMISE seems to be mentioned sporadically throughout the webinar, without any clear link to Portsmouth or severe asthma specifically. Do you have other sources for this?·28.4.I'm looking at the webinar slide about "Funding priority" where "OPTIMISE framework" is mentioned under a section marked with "COPD only". And it's also mentioned in connection with feedback from many other sites than Portsmouth. As far as I know, no testing of Induct with COPD has started yet, and certainly not around many sites. So I currently consider your connection OPTIMISE = Induct as fantasy.- ·27.4.How should one interpret 0 info released from the important meeting, is Induct suddenly one of many potential software suppliers for the same project?27.4.27.4.None of the listed software on the RTP meeting slides has anything to do with Inducts software
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
80 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·29.4.Perhaps this could be significant for Induct in the long term: AstraZeneca has received significant US regulatory approvals for two of its key medicines: Breztri for asthma treatment and Saphnelo for self-administration in systemic lupus erythematosus (SLE). These approvals expand treatment options and convenience for patients. The company is also preparing to publish its first-quarter report, while analysts maintain a positive view on the stock. AstraZeneca's Breztri Aerosphere received US FDA approval for maintenance treatment of asthma in adult and pediatric patients aged 12 years and older, marking its second indication after COPD. The US FDA approved Saphnelo (anifrolumab) for self-administration via a once-weekly autoinjector (Saphnelo Pen) for adult patients with systemic lupus erythematosus (SLE), improving patient convenience and accessibility.·3 päivää sitten@Kontormannen can you just stop writing. You show that you have zero insight into the case and every word you come up with is just garbage that provides negative value for a potentially constructive conversation.. It's healthy to bring up potential negative aspects of a company, but garbage belongs in the trash can..
- ·28.4.Slides from the presentation: https://www.healthinnovationoxford.org/wp-content/uploads/2026/04/RTP-Launch-Webinar-23-April-slides-1.pdf recording: https://youtu.be/ZwawwQR0c1c
- ·28.4.Who is constantly selling? Is there anyone with an endless number of shares? Is anyone benefiting from selling cheap? Anyone following the largest positions and can say something? This is the least shareholder-friendly company I have owned, considering the lack of info and marketing. It's going incredibly slow from the company's side, which still has yet to deliver on expectations…·29.4.As several have mentioned previously, it is likely Kimpot AS and NPP Capital who have sold off large stakes. Whether this is the case now is not known, as I don't have the latest figures.
- 2 päivää sitten2 päivää sittenTämä julkaisu on poistettu.·27.4. · Muokattu@Eivloek I find no connection between OPTIMISE and Induct's module in Portsmouth. OPTIMISE seems to be mentioned sporadically throughout the webinar, without any clear link to Portsmouth or severe asthma specifically. Do you have other sources for this?·28.4.I'm looking at the webinar slide about "Funding priority" where "OPTIMISE framework" is mentioned under a section marked with "COPD only". And it's also mentioned in connection with feedback from many other sites than Portsmouth. As far as I know, no testing of Induct with COPD has started yet, and certainly not around many sites. So I currently consider your connection OPTIMISE = Induct as fantasy.
- ·27.4.How should one interpret 0 info released from the important meeting, is Induct suddenly one of many potential software suppliers for the same project?27.4.27.4.None of the listed software on the RTP meeting slides has anything to do with Inducts software
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Euronext Growth Oslo
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 13.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 13.11.2025 | ||
2025 Q2 -tulosraportti 14.8.2025 | ||
2025 Q1 -tulosraportti 10.4.2025 | ||
2024 Q4 -tulosraportti 13.2.2025 |
2025 Q4 -tulosraportti
Vain PDF
80 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 13.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 13.11.2025 | ||
2025 Q2 -tulosraportti 14.8.2025 | ||
2025 Q1 -tulosraportti 10.4.2025 | ||
2024 Q4 -tulosraportti 13.2.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·29.4.Perhaps this could be significant for Induct in the long term: AstraZeneca has received significant US regulatory approvals for two of its key medicines: Breztri for asthma treatment and Saphnelo for self-administration in systemic lupus erythematosus (SLE). These approvals expand treatment options and convenience for patients. The company is also preparing to publish its first-quarter report, while analysts maintain a positive view on the stock. AstraZeneca's Breztri Aerosphere received US FDA approval for maintenance treatment of asthma in adult and pediatric patients aged 12 years and older, marking its second indication after COPD. The US FDA approved Saphnelo (anifrolumab) for self-administration via a once-weekly autoinjector (Saphnelo Pen) for adult patients with systemic lupus erythematosus (SLE), improving patient convenience and accessibility.·3 päivää sitten@Kontormannen can you just stop writing. You show that you have zero insight into the case and every word you come up with is just garbage that provides negative value for a potentially constructive conversation.. It's healthy to bring up potential negative aspects of a company, but garbage belongs in the trash can..
- ·28.4.Slides from the presentation: https://www.healthinnovationoxford.org/wp-content/uploads/2026/04/RTP-Launch-Webinar-23-April-slides-1.pdf recording: https://youtu.be/ZwawwQR0c1c
- ·28.4.Who is constantly selling? Is there anyone with an endless number of shares? Is anyone benefiting from selling cheap? Anyone following the largest positions and can say something? This is the least shareholder-friendly company I have owned, considering the lack of info and marketing. It's going incredibly slow from the company's side, which still has yet to deliver on expectations…·29.4.As several have mentioned previously, it is likely Kimpot AS and NPP Capital who have sold off large stakes. Whether this is the case now is not known, as I don't have the latest figures.
- 2 päivää sitten2 päivää sittenTämä julkaisu on poistettu.·27.4. · Muokattu@Eivloek I find no connection between OPTIMISE and Induct's module in Portsmouth. OPTIMISE seems to be mentioned sporadically throughout the webinar, without any clear link to Portsmouth or severe asthma specifically. Do you have other sources for this?·28.4.I'm looking at the webinar slide about "Funding priority" where "OPTIMISE framework" is mentioned under a section marked with "COPD only". And it's also mentioned in connection with feedback from many other sites than Portsmouth. As far as I know, no testing of Induct with COPD has started yet, and certainly not around many sites. So I currently consider your connection OPTIMISE = Induct as fantasy.
- ·27.4.How should one interpret 0 info released from the important meeting, is Induct suddenly one of many potential software suppliers for the same project?27.4.27.4.None of the listed software on the RTP meeting slides has anything to do with Inducts software
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Euronext Growth Oslo
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt